After utilization clinical use of PSA, a “stage shift “ emerged for prostate cancer. By means of this, as it shown in SEER trial, a reduction of 35,5% in mortality rate could be obtained. The people who claimed the benefit of surveillance said that, the prostate cancers diagnosed by the mean of this are mostly organ confined and have a chance of long survive. The people against this says that the decrease in mortality not directly related to surveillance but related to well medical care that give to surveyed people and also to emerging developments in medicine. At the and, surveillance is more suitable to young and long life expectancy population.

For the issue of prevention for prostate cancer, various chemical and phytotherapeutic drugs and nutritive regimes and also 5-alpha reductase inhibitors (ARI) were examined. It was pointed out in PCPT trial that, a daily intake of 5 mgs. finasteride reduces by 24,8% the risk of development of prostate cancer. There will be more clear information available after the conclusion of many phase III trials that are going on with various nutrition regimes and drugs.